Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/133837
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sicras Mainar, Antoni | - |
dc.contributor.author | Rejas, Javier | - |
dc.contributor.author | Pérez-Paramo, Maria | - |
dc.contributor.author | Sánchez-Álvarez, Luis | - |
dc.contributor.author | Navarro-Artieda, Ruth | - |
dc.contributor.author | Darbà, Josep | - |
dc.date.accessioned | 2019-05-24T07:41:51Z | - |
dc.date.available | 2020-02-28T06:10:17Z | - |
dc.date.issued | 2019-02 | - |
dc.identifier.issn | 1473-7167 | - |
dc.identifier.uri | http://hdl.handle.net/2445/133837 | - |
dc.description.abstract | Background: Discrepancies are seen between arguments in favor of and against prescribing generic versus brand-name drugs. Objective: To provide real-world evidence on treatment persistence, economic and clinical outcomes of pregabalin, generic versus brand-name (Lyrica®, Pfizer), routinely used to treat neuropathic pain (NP) or generalized anxiety disorder (GAD). Methods: Electronic medical records from subjects' first starting treatment with pregabalin between January-2015 and June-2016 were analyzed. Persistence, resources utilization, and costs were assessed, along with remitter and responder rates. (...) | - |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Informa Healthcare | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1080/14737167.2019.1519399 | - |
dc.relation.ispartof | Expert Review of Pharmacoeconomics & Outcomes Research, 2019, vol. 19, num. 1, p. 45-57 | - |
dc.relation.uri | https://doi.org/10.1080/14737167.2019.1519399 | - |
dc.rights | (c) Informa Healthcare, 2019 | - |
dc.source | Articles publicats en revistes (Economia) | - |
dc.subject.classification | Medicaments | - |
dc.subject.classification | Medicaments genèrics | - |
dc.subject.classification | Anàlisi cost-benefici | - |
dc.subject.classification | Neuropsicofarmacologia | - |
dc.subject.classification | Tractament del dolor | - |
dc.subject.classification | Ansietat | - |
dc.subject.other | Drugs | - |
dc.subject.other | Generic drugs | - |
dc.subject.other | Cost effectiveness | - |
dc.subject.other | Neuropsychopharmacology | - |
dc.subject.other | Pain treatment | - |
dc.subject.other | Anxiety | - |
dc.title | Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 686010 | - |
dc.date.updated | 2019-05-24T07:41:51Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Economia) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
686010.pdf | 449.11 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.